newsfilter
← Latest News
GlobeNewswire·

Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline

  • Oculis Holding AG announced an in-person & virtual R&D Day on December 8, 2026, at the St. Regis New York at 10:00 EST.
  • The event will highlight clinical & strategic updates for Licaminlimab in dry eye disease & Privosegtor in neuro-ophthalmology & neurology.
  • Confirmed Key Opinion Leaders include Christophe Baudouin, Jeffrey Bennett, Anat Galor, Ludwig Kappos, Mark Kupersmith, Wolf A. Lagrèze, & Céline Louapre.
  • Licaminlimab presentations will cover PREDICT-1 registrational trial results for TNFR1-mediated dry eye disease, with top-line data expected by year-end.
  • Privosegtor updates will focus on the PIONEER program milestones for optic neuritis & the clinical roadmap for acute multiple sclerosis relapse.
  • Oculis management will introduce recent hires Prof. Björn Tackenberg as Chief Scientific Officer & Aaron Tansy as Franchise Head of Neurology.
  • Licaminlimab is an investigational anti-TNFα eye drop candidate utilizing scFv technology with a genotype-based approach for precision medicine.
  • Privosegtor is a novel peptoid small-molecule candidate with Breakthrough Therapy & Orphan Drug designations for optic neuritis.
  • Optic neuritis is an acute inflammation of the optic nerve affecting up to 8 per 100,000 people, often serving as the first sign of multiple sclerosis.
  • Acute multiple sclerosis relapses currently lack approved neuroprotective therapies, creating an unmet medical need to prevent long-term disability.
  • Oculis is a global biopharmaceutical company headquartered in Switzerland with operations in the U.S. & Iceland.
Company
Oculis Holding AG
Keywords
Nasdaq:OCS, Oculis Holding AG